


EVOcells Oncology: an end-to-end platform for iPSC-based immune cell therapeutics enabling a streamlined manufacturing process




A flexible toolbox to create a universe of innovative cell therapy projects


Immune cell types	A comprehensive portfolio of early iPSC-based immune cell therapy assets						
Validated genetic modifications	Program/Project	Partner	Disease area	Protocol development	Pre-clinical research	Pre-clinical development	IND / Phase I
+	iNK		Oncology				1)
	iMAC		Oncology				
+	γδ iT	Pharma partner	Oncology		Undisclosed		
	αβ iT		Oncology				

Targeting moieties
CAR and EVOIce bispecifics

Scalable and GMP-compatible 3D differentiation process for iNK cells




Homogenous population of NK cells produced from GMP iPSC line in bioreactor





3D production in bioreactors generates highly pure iNK cells and facilitates upscaling for clinical production


iNK are comparable to blood-derived NK cells




CD19-CAR iNK or iNK combined to biologics successfully target primary tumor cells derived from patients suffering from CLL and ALL



Robust 3D process to differentiate iMACs using a GMP-grade iPSC line



M1-polarized iMACs kill primary tumor cells when directed with clinical-grade antibodies



Conclusion

- EVOcells Oncology is a fully integrated R&D engine with key proprietary technologies
- Truly "off-the-shelf", fully scalable cell therapy products
- Expertise to produce various immune cell types with innovative engineering strategies
- Cell therapy GMP manufacturing site to deliver clinical candidates